Synergistic combination of antioxidants, silver nanoparticles and chitosan in a nanoparticle based formulation: Characterization and cytotoxic effect on MCF-7 breast cancer cell lines

详细信息    查看全文

• 作者：Debasis Nayak^a ; Aliva Prity Minz^a ; Sarbani Ashe^a ; Pradipta Ranjan Rauta^a ; Manisha Kumari^a ; Pankaj Chopra^b ; Bismita Nayak^a ; ^{nayakb@nitrkl.a.cin" class="auth_mail" title="E-mail the corresponding author} ; ^{bismita.nayak@gmail.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Nanoparticles ; Antioxidants ; Chitosan ; Silver nanoparticles ; Vitamin E ; Vitamin C ; Targeted drug delivery ; Anti-cancer activity ; Hemocompatible
• 刊名：Journal of Colloid and Interface Science
• 出版年：2016
• 出版时间：15 May 2016
• 年：2016
• 卷：470
• 期：Complete
• 页码：142-152
• 全文大小：2917 K

文摘

Chitosan (Cs) is a biocompatible, biodegradable cationic polymer having the ability of targeted drug delivery. Vitamin E and C are not synthesized in our body thus, when encapsulated within a carrier system these vitamins in combination with/alone can be utilized for their anti-cancer potentials.

Experiment

The present investigation was conducted to develop a stable nanoparticle based formulation encapsulating antioxidants (Vitamin E, catechol) and silver nanoparticles synthesized from Hibiscus rosa-sinensis (HRS) petal extracts within a chitosan matrix. The prepared nanoformulations were characterized using Field emission scanning electron microscopy (Fe-SEM), X-ray diffraction (XRD) and Attenuated Total Reflection Fourier Transform Infrared spectroscopy (ATR-FTIR). They were further tested for their antioxidant potentials using DPPH assay, hydrogen peroxide scavenging assay, nitric oxide scavenging assay and ferrous antioxidant reducing potential assay.

Findings

The nanoformulations were found to be highly hemocompatible and showed high encapsulation efficiency up to 76%. They also showed higher antioxidant activity than their base materials. Further, their anti-cancer efficacy was observed against MCF-7 breast cancer cells having IC₅₀ values of 53.36 ± 0.36 μg/mL (chitosan–ascorbic acid–glucose), 55.28 ± 0.85 μg/mL (chitosan–Vitamin E), 63.72 ± 0.27 μg/mL (Chitosan–catechol) and 58.53 ± 0.55 μg/mL (chitosan–silver nanoparticles). Thus, the prepared formulations can be therapeutically applied for effective and targeted delivery in breast cancer treatment.